

Jennifer Blanchette, PhD<sup>1</sup>; Jenny Schulz, PhD<sup>1</sup>; Edward King, MA<sup>1</sup>; Brian Wood, MD<sup>2</sup>; Joseph J. Eron, MD<sup>3</sup>; Paul E. Sax, MD<sup>4</sup>

1. Clinical Care Options, LLC, Reston, VA. 2. University of Washington, Seattle, WA. 3. University of North Carolina at Chapel Hill, Chapel Hill, NC. 4. Brigham and Women's Hospital, Boston, MA


## 1. Background

- Patients may consider switching suppressive HIV regimens for a variety of reasons, including simplification, improved safety and tolerability, drug interactions, or cost
- Because switching treatment is a common clinical dilemma in current HIV care, we developed an online treatment decision support tool to assist providers in selecting a new regimen in a variety of patient scenarios

## 2. Methods

- In March 2018, 5 HIV experts provided treatment recommendations for 1360 unique HIV switch case scenarios based on a simplified set of patient variables:
  - HLA-B\*5701 status
  - ARV drug resistance
  - Presence of or high risk for CVD
  - HBV coinfection
  - Current ART regimen and component requiring a switch
- We then developed an online decision support tool that enabled clinicians to specify a patient scenario using these variables and then see the experts' recommendations for that specific case. Users' treatment intentions were captured before and after recommendations were displayed


### Online Decision Support Tool Provides Patient-Specific Recommendations From 5 HIV Experts



[www.clinicaloptions.com/hiv/programs/hiv-switch/interactive-decision-support-tool/](http://www.clinicaloptions.com/hiv/programs/hiv-switch/interactive-decision-support-tool/)

## 3. Participant Demographics



- From March 2018 through April 2019, N = 835 participants (69% ID or HIV specialists) entered 1364 patient case scenarios




**Disclosures:** 1. None. 2. None. 3. Funds for research support from Gilead Sciences, Janssen, and ViiV Healthcare and consulting fees from Gilead Sciences, Janssen, Merck, and ViiV Healthcare 4. Funds for research support from Gilead Sciences and ViiV Healthcare and fees for advisor or review panel member from Gilead Sciences, Janssen, and Merck.

## 4. Comparison of Switch Regimen Choice by Patient Scenario

### All Cases in Which Users' Baseline Switch Intentions Inconsistent With Expert Recommendations




- Inconsistent with experts
- Consistent with experts




## 5. Intent to Change Among Participants Differing From Experts

Did Not Change Plan Owing to Barriers, Disagreement With Experts, Unsure (58%)



Changed Plan/Agree With Experts (42%)



"This is a very useful tool and it is always important to have the advice of an expert; thanks for the support"

"This was fun, easy to use, and quite helpful!"

## 6. Conclusions

- This online decision support tool showed that clinicians' initially planned switch regimen for patients requiring a change in ART for reasons other than virologic failure differed from HIV experts for 64% of case scenarios; rate of difference increased as cases became more complex
- Scenarios where clinicians' treatment plan was inconsistent with expert selections were:
  - Users more often selected boosted regimens overall, particularly boosted PIs
  - Users and experts differed in their use of dual therapy option DTG/RPV
  - TDF-containing regimens: never selected by experts vs 11% of participant cases
- Using an online tool changed the intended treatment plan for many participants, suggesting the tool's use can help optimize the selection of a switch regimen in patients with virologic suppression on their current ART regimen

**Acknowledgements:** This research is based on CME activities supported by an independent educational grant from Gilead Sciences.